Pieris AG
USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, recorded in grant years 2015–2016. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).
The verdict
According to USPTO PatentsView, Pieris ranks #42,343 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 5 technology areas.
- #42,343
- of 49,997 US assignees by volume
- 17th percentile
- by Innovation Score (25.2/100)
- 17.7
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R42343 · Foreign Corporation #42,343 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 6 grants
- LOWER-Q #42,343/49,997
- PHOTO-FINISH Photopotech
- CPC-NARROW C07K · 5 areas
- INNOV-THIN 25.2/100
- CLAIMS-RICH 17.7 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Photopotech LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Pieris’s 25.2 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Pieris
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Pieris · this assignee 25
Pieris · this assignee
25 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Pieris's Innovation Score is 25.2/100 (17th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Pieris?
Each dot is one of Pieris’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Pieris’s own 17.7 claims/patent is ABOVE the 14.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Pieris's grants concentrate
Pieris AG is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2015 (5 grants) versus a trough of 1 in 2016. By volume, Pieris sits between Photopotech LLC and Pinpoint Ideas, LLC.
Who files at Pieris's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Photopotech
Photopotech LLC
6 patents
- Phyton Holdings
Phyton Holdings, LLC
6 patents
- Picscout (Israel)
PicScout (Israel) Ltd.
6 patents
- Piedmont Animal H…
Piedmont Animal Health Inc.
6 patents
- Pike Brands
Pike Brands LLC
6 patents
- Pile Dynamics
Pile Dynamics, Inc.
6 patents
- Pink Adventure Gr…
Pink Adventure Group, Inc.
6 patents
- Pinpoint Ideas
Pinpoint Ideas, LLC
6 patents
- Pieris ◀
Pieris AG
6 patents
What this shows Pieris holds 6 patents at rank #42,394, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Pieris
By rank, the assignees closest to #42,394 in granted patent volume.
- Photopotech LLC #42,390 · 6 patents
- Phyton Holdings, LLC #42,391 · 6 patents
- PicScout (Israel) Ltd. #42,392 · 6 patents
- Piedmont Animal Health Inc. #42,393 · 6 patents
- Pike Brands LLC #42,395 · 6 patents
- Pile Dynamics, Inc. #42,396 · 6 patents
- Pink Adventure Group, Inc. #42,397 · 6 patents
- Pinpoint Ideas, LLC #42,398 · 6 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Pieris's primary technology class.
- The Regents of the University of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies GmbH 678 in class
- Genentech, Inc. 565 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 513 in class
- The Trustees of the University of Pennsylvania 501 in class
- Novartis AG 407 in class
- The Board of Trustees of the Leland Stanford Junior University 400 in class
Pieris's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
25 17th percentile higher than 17% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 5 | 83.3% |
| 2016 | 1 | 16.7% |
Which technologies does Pieris AG patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Pieris AG's patent record in context - here's where to go next.
- Pieris AG's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
- Ranked #42,343 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Pieris AG against Photopotech LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 25.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.